Risk Factors for Amisulpride-Associated Hyperprolactinemia: Gender-Specific Plasma Concentration Cutoffs Derived from ROC Analysis
Drug Design, Development and Therapy · 2026-08 · Volume 20 · 1-16
DOI: 10.2147/dddt.s633999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-08. Verfasst von Hui Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xi'an Mental Health Center, Xi'an, Shaanxi, 710100, People's Republic of China. Hauptthemen laut MEDLINE: Hyperprolactinemia, Amisulpride, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xi'an Mental Health Center, Xi'an, Shaanxi, 710100, People's Republic of China.
ORCID-Profile: Hui Wang
Zitieren
APA
Wang, H., Shao, Q., Yang, M., Chen, Y., & Wang, W. (2026). Risk Factors for Amisulpride-Associated Hyperprolactinemia: Gender-Specific Plasma Concentration Cutoffs Derived from ROC Analysis. Drug Design, Development and Therapy, Volume 20, 1-16. https://doi.org/10.2147/dddt.s633999
Vancouver
Wang H, Shao Q, Yang M, Chen Y, Wang W. Risk Factors for Amisulpride-Associated Hyperprolactinemia: Gender-Specific Plasma Concentration Cutoffs Derived from ROC Analysis. Drug Design, Development and Therapy. 2026;Volume 20:1-16. doi:10.2147/dddt.s633999
BibTeX
@article{Wang2026,
author = {Wang, Hui and Shao, Qing and Yang, Miaomiao and Chen, Yichen and Wang, Wenjie},
title = {Risk Factors for Amisulpride-Associated Hyperprolactinemia: Gender-Specific Plasma Concentration Cutoffs Derived from ROC Analysis},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--16},
doi = {10.2147/dddt.s633999}
}
EUVIMED